Every cancer patient deserves the right treatment
for their individual form of cancer.
New The power of precision, For Every Oncologist, Today
At 2cureX, we’re pioneers of 3D microtumors in cancer therapy, focused on improving the outcomes of cancer treatment
2cureX launches IndiTreat® for metastasised colon cancer, the world’s first CE validated IVD based on microtumors
For over 2 decades, testing cancer treatments on microtumors rather than on the patient has been on the horizon. With IndiTreat®, 2cureX makes microtumor testing an operational reality to serve you and your cancer clinic.
IndiTreat CE IVD is available today for identifying effective chemotherapies of certain forms of colorectal cancer if a biopsy is feasible. Ask your doctor if it is possible to consider IndiTreat for your cancer.
Last patient treated in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.
2cureX appoints new CEO (BioStock)
Press ReleasesPress Releases Regulatory
2cureX appoints Fernando Andreu, an international Biotech executive, as new CEO
Key achievements in 2020 – an IndiTreat® Launch year
Get notified on mail, when news or press release is posted on our website